{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Anti-proliferative", "Apoptosis", "Breast cancer", "MD simulations", "Semi synthesis", "Theobromine derivatives", "VEGFR-2 inhibitors"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38028225", "DateRevised": {"Year": "2023", "Month": "12", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "11", "Day": "02"}], "Language": ["eng"], "ELocationID": ["101852", "10.1016/j.jsps.2023.101852"], "Journal": {"ISSN": "1319-0164", "JournalIssue": {"Volume": "31", "Issue": "12", "PubDate": {"Year": "2023", "Month": "Dec"}}, "Title": "Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society", "ISOAbbreviation": "Saudi Pharm J"}, "ArticleTitle": "Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2.", "Pagination": {"StartPage": "101852", "MedlinePgn": "101852"}, "Abstract": {"AbstractText": ["VEGFR-2 is a significant target in cancer treatment, inhibiting angiogenesis and impeding tumor growth. Utilizing the essential pharmacophoric structural properties, a new semi-synthetic theobromine analogue (<b>T-1-MBHEPA</b>) was designed as VEGFR-2 inhibitor. Firstly, <b>T-1-MBHEPA</b>'s stability and reactivity were indicated through several DFT computations. Additionally, molecular docking, MD simulations, MM-GPSA, PLIP, and essential dynamics (ED) experiments suggested <b>T-1-MBHEPA</b>'s strong binding capabilities to VEGFR-2. Its computational ADMET profiles were also studied before the semi-synthesis and indicated a good degree of drug-likeness. <b>T-1-MBHEPA</b> was then semi-synthesized to evaluate the design and the <i>in silico</i> findings. It was found that, <b>T-1-MBHEPA</b> inhibited VEGFR-2 with an IC<sub>50</sub> value of 0.121\u00a0\u00b1\u00a00.051\u00a0\u00b5M, as compared to sorafenib which had an IC<sub>50</sub> value of 0.056\u00a0\u00b5M. Similarly, <b>T-1-MBHEPA</b> inhibited the proliferation of HepG2 and MCF7 cell lines with IC<sub>50</sub> values of 4.61 and 4.85\u00a0\u00b5g/mL respectively - comparing sorafenib's IC<sub>50</sub> values which were 2.24\u00a0\u00b5g/mL and 3.17\u00a0\u00b5g/mL respectively. Interestingly, <b>T-1-MBHEPA</b> revealed a noteworthy IC<sub>50</sub> value of 80.0\u00a0\u00b5M against the normal cell lines exhibiting exceptionally high selectivity indexes (SI) of 17.4 and 16. 5 against the examined cell lines, respectively. <b>T-1-MBHEPA</b> increased the percentage of apoptotic MCF7 cells in early and late stages, respectively, from 0.71\u00a0% to 7.22\u00a0% and from 0.13\u00a0% to 2.72\u00a0%, while the necrosis percentage was increased to 11.41\u00a0%, in comparison to 2.22\u00a0% in control cells. Furthermore, <b>T-1-MBHEPA</b> reduced the production of pro-inflammatory cytokines TNF-\u03b1 and IL-2 in the treated MCF7 cells by 33\u00a0% and 58\u00a0%, respectively indicating an additional anti-angiogenic mechanism. Also, <b>T-1-MBHEPA</b> decreased significantly the potentialities of MCF7 cells to heal and migrate from 65.9\u00a0% to 7.4\u00a0%. Finally, <b>T-1-MBHEPA</b>'s oral treatment didn't show toxicity on the liver function (ALT and AST) and the kidney function (creatinine and urea) levels of mice."], "CopyrightInformation": "\u00a9 2023 The Author(s)."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Chemistry, Faculty of Science, Al-Azhar University, Assiut Branch, 71524, Assiut, Egypt."}], "LastName": "Asmaey", "ForeName": "Mostafa A", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Elkady", "ForeName": "Hazem", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry Department, Faculty of Science, New Valley University, El-Kharja 72511, Egypt."}], "LastName": "Husein", "ForeName": "Dalal Z", "Initials": "DZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Aisha A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Cairo 12613, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo 11231, Egypt."}], "LastName": "Elkady", "ForeName": "Mohamed A", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Saudi Arabia", "MedlineTA": "Saudi Pharm J", "NlmUniqueID": "9705695", "ISSNLinking": "1319-0164"}, "CoiStatement": "The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Alanazi M.M., Eissa I.H., Alsaif N.A., et al. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J. Enzyme Inhib. Med. Chem. 2021;36:1760\u20131782.", "ArticleIdList": ["PMC8344243", "34340610"]}, {"Citation": "Ali, S., M. I. Ullah, A. Sajjad, et al., 2021. Environmental and health effects of pesticide residues. Sustainable Agriculture Reviews 48: Pesticide Occurrence, Analysis and Remediation Vol. 2 Analysis. 311-336."}, {"Citation": "Alley M.C., Scudiero D.A., Monks A., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988;48:589\u2013601.", "ArticleIdList": ["3335022"]}, {"Citation": "Amadei, A., A. B. Linssen, H. J. J. P. S. Berendsen, Function,, et al., 1993. Essential dynamics of proteins. 17, 412-425.", "ArticleIdList": ["8108382"]}, {"Citation": "Angelo L.S., Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin. Cancer Res. 2007;13:2825\u20132830.", "ArticleIdList": ["17504979"]}, {"Citation": "Bai J., Wu J., Tang R., et al. Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR 2 and miR-34a. Invest. New Drugs. 2020;38:229\u2013245.", "ArticleIdList": ["30976957"]}, {"Citation": "Chinedu E., Arome D., Ameh F.S. A new method for determining acute toxicity in animal models. Toxicol. Int. 2013;20:224.", "ArticleIdList": ["PMC3877490", "24403732"]}, {"Citation": "del Carmen Quintal Boj\u00f3rquez, N. and M. R. Campos, 2023. Traditional and Novel Computer-Aided Drug Design (CADD) Approaches in the Anticancer Drug Discovery Process. Current Cancer Drug Targets. 23, 333-345.", "ArticleIdList": ["35792126"]}, {"Citation": "Dietrich J., Hulme C., Hurley L.H. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec\u00ae, Nexavar\u00ae, and BIRB-796. Bioorg. Med. Chem. 2010;18:5738\u20135748.", "ArticleIdList": ["20621496"]}, {"Citation": "Elkady H., Elwan A., El-Mahdy H.A., et al. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J. Enzyme Inhib. Med. Chem. 2022;37:403\u2013416.", "ArticleIdList": ["PMC8725875", "34961427"]}, {"Citation": "Elkady H., Abuelkhir A.A., Rashed M., et al. New thiazolidine-2, 4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies. Comput. Biol. Chem. 2023;107", "ArticleIdList": ["37714080"]}, {"Citation": "Elkady H., El-Dardir O.A., Elwan A., et al. Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2, 4-dione derivatives as potential antitumor VEGFR-2 inhibitors. RSC Adv. 2023;13:27801\u201327827.", "ArticleIdList": ["PMC10508263", "37731835"]}, {"Citation": "Elkaeed E.B., Taghour M.S., Mahdy H.A., et al. New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. J. Enzyme Inhib. Med. Chem. 2022;37:2191\u20132205.", "ArticleIdList": ["PMC9387325", "35975321"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., et al. In silico, in vitro VEGFR-2 inhibition, and anticancer activity of a 3-(hydrazonomethyl) naphthalene-2-ol derivative. J. Biomol. Struct. Dyn. 2022:1\u201316.", "ArticleIdList": ["36184591"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., et al. Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: In vitro anticancer and VEGFR-2 inhibitory effects. Molecules. 2022;27:4606.", "ArticleIdList": ["PMC9317904", "35889478"]}, {"Citation": "Elkaeed E.B., Eissa I.H., Elkady H., et al. A multistage in silico study of natural potential inhibitors targeting SARS-CoV-2 main protease. Int. J. Mol. Sci. 2022;23:8407.", "ArticleIdList": ["PMC9369012", "35955547"]}, {"Citation": "Elkaeed, E. B., R. G. Yousef, H. Elkady, et al., 2022. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects. Molecules. 27, 4606.", "ArticleIdList": ["PMC9317904", "35889478"]}, {"Citation": "Elkaeed, E. B., R. G. Yousef, H. Elkady, et al., 2022. The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1 H-Indole Derivative: In Silico and In Vitro Approaches. Processes. 10, 1391."}, {"Citation": "Elkaeed E.B., Youssef F.S., Eissa I.H., et al. Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease. Int. J. Mol. Sci. 2022;23:6912.", "ArticleIdList": ["PMC9266348", "35805916"]}, {"Citation": "Elton D.C., Boukouvalas Z., Fuge M.D., et al. Deep learning for molecular design\u2014a review of the state of the art. Mol. Syst. Des. Eng. 2019;4:828\u2013849."}, {"Citation": "Elwan A., Abdallah A.E., Mahdy H.A., et al. Modified benzoxazole-based VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, and anti-proliferative evaluation. Molecules. 2022;27:5047.", "ArticleIdList": ["PMC9370530", "35956997"]}, {"Citation": "Erdem L., Giovannetti E., Leon L.G., et al. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr. Top. Med. Chem. 2012;12:1649\u20131659. doi: 10.2174/156802612803531333.", "ArticleIdList": ["10.2174/156802612803531333", "22978339"]}, {"Citation": "Fan J., Fu A., Zhang L. Progress in molecular docking. Quant. Biol. 2019;7:83\u201389."}, {"Citation": "Fathi Maroufi N., Taefehshokr S., Rashidi M.-R., et al. Vascular mimicry: changing the therapeutic paradigms in cancer. Mol. Biol. Rep. 2020;47:4749\u20134765.", "ArticleIdList": ["32424524"]}, {"Citation": "Ferreira L.L., Andricopulo A.D. ADMET modeling approaches in drug discovery. Drug Discov. Today. 2019;24:1157\u20131165.", "ArticleIdList": ["30890362"]}, {"Citation": "Fontanella C., Ongaro E., Bolzonello S., et al. Clinical advances in the development of novel VEGFR2 inhibitors. Ann. Transl. Med. 2014;2:123. doi: 10.3978/j.issn.2305-5839.2014.08.14.", "ArticleIdList": ["10.3978/j.issn.2305-5839.2014.08.14", "PMC4260048", "25568876"]}, {"Citation": "Fujita K.I., Ishida H., Kubota Y., et al. Toxicities of receptor tyrosine kinase inhibitors in cancer pharmacotherapy: Management with clinical pharmacology. Curr. Drug Metab. 2017;18:186\u2013198. doi: 10.2174/1389200218666170105165832.", "ArticleIdList": ["10.2174/1389200218666170105165832", "28059038"]}, {"Citation": "Hartmann J.T., Haap M., Kopp H.G., et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr. Drug Metab. 2009;10:470\u2013481. doi: 10.2174/138920009788897975.", "ArticleIdList": ["10.2174/138920009788897975", "19689244"]}, {"Citation": "Huang L., Huang Z., Bai Z., et al. Development and strategies of VEGFR-2/KDR inhibitors. Future Med. Chem. 2012;4:1839\u20131852.", "ArticleIdList": ["23043480"]}, {"Citation": "Huillard O., Boissier E., Blanchet B., et al. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients. Expert Opin. Drug Saf. 2014;13:663\u2013673. doi: 10.1517/14740338.2014.907270.", "ArticleIdList": ["10.1517/14740338.2014.907270", "24693873"]}, {"Citation": "Idakwo G., Luttrell J., Chen M., et al. A review on machine learning methods for in silico toxicity prediction. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2018;36:169\u2013191. doi: 10.1080/10590501.2018.1537118.", "ArticleIdList": ["10.1080/10590501.2018.1537118", "30628866"]}, {"Citation": "Jonkman J.E., Cathcart J.A., Xu F., et al. An introduction to the wound healing assay using live-cell microscopy. Cell Adh. Migr. 2014;8:440\u2013451.", "ArticleIdList": ["PMC5154238", "25482647"]}, {"Citation": "Kataoka Y., Mukohara T., Tomioka H., et al. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest. New Drugs. 2012;30:1352\u20131360.", "ArticleIdList": ["21655918"]}, {"Citation": "Kinnings S.L., Jackson R.M. Binding site similarity analysis for the functional classification of the protein kinase family. J. Chem. Inf. Model. 2009;49:318\u2013329.", "ArticleIdList": ["19434833"]}, {"Citation": "Kruhlak N.L., Benz R.D., Zhou H., et al. (Q)SAR modeling and safety assessment in regulatory review. Clin. Pharmacol. Ther. 2012;91:529\u2013534. doi: 10.1038/clpt.2011.300.", "ArticleIdList": ["10.1038/clpt.2011.300", "22258468"]}, {"Citation": "Levy A., Benmoussa L., Ammari S., et al. Reversible posterior leukoencephalopathy syndrome induced by axitinib. Clin. Genitourin. Cancer. 2014;12:e33\u2013e34. doi: 10.1016/j.clgc.2013.08.008.", "ArticleIdList": ["10.1016/j.clgc.2013.08.008", "24135633"]}, {"Citation": "Li X., Chai J., Wang Z., et al. Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review. OncoTargets Ther. 2018;11:4407\u20134411. doi: 10.2147/ott.S166605.", "ArticleIdList": ["10.2147/ott.S166605", "PMC6072830", "30104882"]}, {"Citation": "Lugano R., Ramachandran M., Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 2020;77:1745\u20131770.", "ArticleIdList": ["PMC7190605", "31690961"]}, {"Citation": "Luo G., Li X., Zhang G., et al. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton-A possible way to dual ER\u03b1/VEGFR-2 ligands for treatment of breast cancer. Eur. J. Med. Chem. 2017;140:252\u2013273.", "ArticleIdList": ["28942113"]}, {"Citation": "Machado V.A., Peixoto D., Costa R., et al. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-ylthio) phenyl] ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorg. Med. Chem. 2015;23:6497\u20136509.", "ArticleIdList": ["26344591"]}, {"Citation": "Modi S.J., Kulkarni V.M. Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: medicinal chemistry perspective. Med. Drug Discov. 2019;2"}, {"Citation": "Moradi M., Mousavi A., Emamgholipour Z., et al. Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies. Eur. J. Med. Chem. 2023", "ArticleIdList": ["37453330"]}, {"Citation": "Nascimento, I. J. d. S., T. M. de Aquino and E. F. da Silva-J\u00fanior, 2022. The new era of drug discovery: The power of computer-aided drug design (CADD). Letters in Drug Design & Discovery. 19, 951-955."}, {"Citation": "NDC, Q. B. and M. Campos, 2022. Traditional and Novel Computer-Aided Drug Design (CADD) Approaches in the Anticancer Drug Discovery Process Computer-Aided Drug Design (CADD) Approaches in the Development of Anticancer Drugs. Current Cancer Drug Targets.", "ArticleIdList": ["35792126"]}, {"Citation": "Obot I., Macdonald D., Gasem Z. Density functional theory (DFT) as a powerful tool for designing new organic corrosion inhibitors. Part 1: an overview. Corros. Sci. 2015;99:1\u201330."}, {"Citation": "Ou X.-M., Li W.-C., Liu D.-S., et al. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice. Int. Immunopharmacol. 2009;9:70\u201379.", "ArticleIdList": ["18976720"]}, {"Citation": "Papaleo, E., P. Mereghetti, P. Fantucci, et al., 2009. Free-energy landscape, principal component analysis, and structural clustering to identify representative conformations from molecular dynamics simulations: the myoglobin case. 27, 889-899.", "ArticleIdList": ["19264523"]}, {"Citation": "Reker D., Schneider G. Active-learning strategies in computer-assisted drug discovery. Drug Discov. Today. 2015;20:458\u2013465.", "ArticleIdList": ["25499665"]}, {"Citation": "Rodriguez, L. G., X. Wu and J.-L. Guan, 2005. Wound-healing assay. Cell Migration: Developmental Methods and Protocols. 23-29.", "ArticleIdList": ["15576902"]}, {"Citation": "Schmidt S., Gonzalez D., Derendorf H. Significance of protein binding in pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 2010;99:1107\u20131122.", "ArticleIdList": ["19852037"]}, {"Citation": "Shacter, E. and S. A. Weitzman, 2002. Chronic inflammation and cancer. Oncology (Williston Park, NY). 16, 217-226, 229; discussion 230.", "ArticleIdList": ["11866137"]}, {"Citation": "Shah A.A., Kamal M.A., Akhtar S. Tumor angiogenesis and VEGFR-2: mechanism, pathways and current biological therapeutic interventions. Curr. Drug Metab. 2021;22:50\u201359.", "ArticleIdList": ["33076807"]}, {"Citation": "Shi L., Zhou J., Wu J., et al. Anti-angiogenic therapy: Strategies to develop potent VEGFR-2 tyrosine kinase inhibitors and future prospect. Curr. Med. Chem. 2016;23:1000\u20131040.", "ArticleIdList": ["26860998"]}, {"Citation": "Sivaraj K.K., Takefuji M., Schmidt I., et al. G13 controls angiogenesis through regulation of VEGFR-2 expression. Dev. Cell. 2013;25:427\u2013434.", "ArticleIdList": ["23664862"]}, {"Citation": "Spannuth W.A., Nick A.M., Jennings N.B., et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int. J. Cancer. 2009;124:1045\u20131053.", "ArticleIdList": ["PMC2668132", "19058181"]}, {"Citation": "Taghour M.S., Elkady H., Eldehna W.M., et al. Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies. J. Biomol. Struct. Dyn. 2022:1\u201316.", "ArticleIdList": ["36617888"]}, {"Citation": "Taghour M.S., Elkady H., Eldehna W.M., et al. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2, 4-diones targeting VEGFR-2 and apoptosis pathway. PLoS One. 2022;17:e0272362.", "ArticleIdList": ["PMC9506633", "36149902"]}, {"Citation": "Taghour M.S., Elkady H., Eldehna W.M., et al. Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-vitro anticancer evaluation and in-silico studies. J. Enzyme Inhib. Med. Chem. 2022;37:1903\u20131917.", "ArticleIdList": ["PMC9272924", "35801403"]}, {"Citation": "Tesa\u0159ov\u00e1 P., Tesa\u0159 V. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway\u2013incidence, mechanisms and management. Folia Biol. 2013;59:15\u201325.", "ArticleIdList": ["23537524"]}, {"Citation": "Thakur, M. and D. Pathania, 2020. Environmental fate of organic pollutants and effect on human health. Abatement of Environmental Pollutants, Elsevier: 245-262."}, {"Citation": "Tian S., Quan H., Xie C., et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102:1374\u20131380.", "ArticleIdList": ["21443688"]}, {"Citation": "Van de Loosdrecht, A., R. Beelen, g. Ossenkoppele, et al., 1994. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. Journal of immunological methods. 174, 311-320.", "ArticleIdList": ["8083535"]}, {"Citation": "Wang X., Bove A.M., Simone G., et al. Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front. Cell Dev. Biol. 2020;8", "ArticleIdList": ["PMC7701214", "33304904"]}, {"Citation": "Wang T., Husein D.Z. Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: Disposing of waste with waste. Environ. Sci. Pollut. Res. 2023;30:8928\u20138955.", "ArticleIdList": ["35460480"]}, {"Citation": "Wang Z., Wang N., Han S., et al. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One. 2013;8:e68566.", "ArticleIdList": ["PMC3702614", "23861918"]}, {"Citation": "Yan J.-D., Liu Y., Zhang Z.-Y., et al. Expression and prognostic significance of VEGFR-2 in breast cancer. Pathol.-Res. Pract. 2015;211:539\u2013543.", "ArticleIdList": ["25976977"]}, {"Citation": "Yang X., Wang Y., Byrne R., et al. Concepts of artificial intelligence for computer-assisted drug discovery. Chem. Rev. 2019;119:10520\u201310594.", "ArticleIdList": ["31294972"]}, {"Citation": "Yousef R.G., Elkady H., Elkaeed E.B., et al. (E)-N-(3-(1-(2-(4-(2, 2, 2-Trifluoroacetamido) benzoyl) hydrazono) ethyl) phenyl) nicotinamide: A novel pyridine derivative for inhibiting vascular endothelial growth factor receptor-2: Synthesis, computational, and anticancer studies. Molecules. 2022;27:7719.", "ArticleIdList": ["PMC9697799", "36431818"]}, {"Citation": "Yousef R.G., Elwan A., Gobaara I.M., et al. Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies. J. Enzyme Inhib. Med. Chem. 2022;37:2206\u20132222.", "ArticleIdList": ["PMC9466619", "35980113"]}, {"Citation": "Zhang, Y., X. Ding, C. Miao, et al., 2019. Propofol attenuated TNF-\u03b1-modulated occludin expression by inhibiting Hif-1\u03b1/VEGF/VEGFR-2/ERK signaling pathway in hCMEC/D3 cells. 19, 1-11.", "ArticleIdList": ["PMC6617648", "31288745"]}, {"Citation": "Zhu, H. and B. I. Rini, 2015. Third-Generation TKIs (Axitinib, Tivozanib) in RCC: Enhanced Efficacy and Diminished Toxicity? Renal Cell Carcinoma: Molecular Targets and Clinical Applications. 217-236."}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "8", "Day": "12"}, {"Year": "2023", "Month": "10", "Day": "30"}, {"Year": "2023", "Month": "11", "Day": "29", "Hour": "18", "Minute": "43"}, {"Year": "2023", "Month": "11", "Day": "29", "Hour": "18", "Minute": "42"}, {"Year": "2023", "Month": "11", "Day": "29", "Hour": "17", "Minute": "11"}, {"Year": "2023", "Month": "11", "Day": "2"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38028225", "PMC10663924", "10.1016/j.jsps.2023.101852", "S1319-0164(23)00347-X"]}}], "PubmedBookArticle": []}